Tiffany Harris-Brown

TL;DR: Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality, and findings do not support use of piperACillin- tazobactsam in this setting.

TL;DR: Poor reliability in susceptibility testing performance for piperacillin/tazobactam and the high prevalence of OXA co-harboring ESBLs suggests meropenem remains the preferred choice for definitive treatment of ceftriaxone non-susceptible E. coli and Klebsiella.

TL;DR: This study will use a multicentre randomised controlled open-label non-inferiority trial design comparing two treatments, meropenem and piperacillin-tazobactam (carbapenem-sparing arm) in adult patients with bacteraemia caused by E. coli or Klebsiella spp, demonstrating non-susceptibility to third generation cephalosporins.

TL;DR: The potential for using social media tools as cost-efficient and mass education platforms to raise awareness of appropriate antibiotic use in the general public and in the medical communities of the Arabian Peninsula is discussed.

TL;DR: A multicenter randomized controlled trial was conducted in this paper, where patients were assigned to receive Piperacillin-tazobactam 4.5 g every 6 hours or meropenem 1 g every 8 hours and the primary efficacy outcome was a composite of death, clinical failure, microbiological failure, and microbiological relapse at 30 days.